POINT Biopharma Global Inc. announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors. Dr. Martell is a seasoned pharmaceutical executive with a demonstrated track record in both drug development and financing, building, and leading highly successful biotech companies. She started her pharmaceutical career at Pfizer, where she had roles of increasing responsibility in both the oncology and biosimilars business units.

Dr. Martell has held leadership and C-suite executive roles at companies including Kura Oncology and Juniper Pharmaceuticals, and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla, Elelyso, Intermezzo, the trastuzumab biosimilar Ogiviri, as well as secondary indications for Pradaxa and Sutent. Dr. Martell is currently President and Chief Executive Officer of Artizan Biosciences Inc., a precision medicine drug development platform company focusing on inflammatory disease and the microbiome. She holds a B.Sc.

in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from the Chicago Medical School.